Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04718896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
April 6, 2021
Completion date
March 12, 2025
Enrollment
41 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis